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CHAPTER 1 INTRODUCTION 
Cancer is a heterogeneous group of diseases characterized by the uncontrolled 
growth and migration of abnormal cells. Cancers arise due to the accumulation of 
genetic and epigenetic alterations leading to aberrant cellular proliferation and/or 
reduced cell death (1, 2). At the time of this writing, cancer is the second leading cause 
of death in the United States, with an approximately 600,000 deaths predicted in 2016; 
it accounts for nearly 1 in every 4 deaths (3, 4). Since 1990, a decline of roughly 1% per 
year in overall cancer mortality has been observed, due to a reduction in cancer risk 
factors, improved early-detection methods, and better therapies (5, 6). Critical to the 
latter two points have been advances in the field of cancer imaging.  
Technical progress in ultrasonography (US), computed tomography (CT) and 
magnetic resonance imaging (MRI) has greatly improved the diagnosis and staging of 
solid tumors by enhancing visualization of the anatomic details of tumors (7, 8). 
Improved detection and staging, in turn, allows for the optimization of therapy and 
potentially the use of curative approaches, such as surgical resection (9, 10). 
Furthermore, anatomic tumor measurements obtained from CT or MRI remain the basis 
for Response Evaluation Criteria in Solid Tumors (RECIST), used widely today in both 
clinical trials and routine oncologic practice (11). Anatomic imaging, however, is not 
without its limitations. Conclusions regarding tumor growth rate and cellularity cannot be 
drawn from CT or MR images. Moreover, it can be difficult to determine the efficacy of 
anti-neoplastic treatment using only measurements of tumor size. For instance, the slow 
growth rate of many solid tumors means that it may take weeks or months for treatment 
failure to become evident (12). Alternatively, successful treatment may leave a fibrotic 
mass that may persist for weeks or months.  
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To overcome these shortcomings, anatomic imaging is now regularly combined 
with molecular imaging techniques, which facilitate the non-invasive monitoring of 
cellular and subcellular processes, allowing for a greater understanding of cancer 
physiology (13, 14). Perhaps the most salient example is the use of positron emission 
tomography (PET) with 18F-labeled 2’-deoxy-2’-fluoro-D-glucose (FDG). PET imaging 
with FDG exploits increased glycolysis in tumors, providing a way to discriminate 
between malignant and normal tissue (15-19).  
Anatomic imaging modalities commonly used in oncology 
The focus of this dissertation will be the use of PET imaging in cancer models, 
and while PET can provide important information on tumor physiology and biochemistry, 
relatively low spatial resolution means that important anatomical information is often not 
present in PET images (20). For that reason, PET is often combined with anatomic 
imaging modalities, allowing for the visualization of both tumor structure and molecular 
biology. Therefore, anatomic imaging techniques including CT, MRI, and US will be 
briefly reviewed, followed by an emphasis on PET imaging.  
CT scans utilize a series of x-ray images taken from multiple angles to produce a 
three-dimensional reconstruction of patient anatomy (21-23). Because of its speed, 
cost-effectiveness, and high resolution, CT is one of the most commonly used imaging 
modalities for the detection of solid tumors (9, 13). Further, the use of CT is now a 
critical element of routine cancer screening (24-27). The National Lung Screening Trial 
demonstrated that annual screening with low-dose CT (LDCT) reduced lung cancer 
mortality by 20% in current and former smokers (28, 29). CT can also be used to 
complement the metabolic images obtained with PET and correct for attenuation of the 
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radioactive probes used with PET. The major disadvantage of CT is that because 
tissues are distinguished based solely on differences in x-ray attenuation, soft tissue 
resolution is relatively poor, and little molecular information can be obtained.  
The basis of MRI is nuclear spin. Atoms with an odd number of protons and 
neutrons, such as 1H, 3He, 23Na or 31P have a non-zero nuclear spin, and therefore 
exhibit a magnetic moment (30). Following excitation by a strong external magnetic 
field, these atoms emit a radio frequency signal as they return to equilibrium (31, 32). 
Cancers can be distinguished from normal tissues by the difference in the rate at which 
atoms return to their equilibrium state (33, 34). A key advantage of MRI over other 
modalities is that it offers excellent spatial resolution and anatomic detail without 
exposing patients to ionizing radiation. Aside from its use in cancer diagnosis, screening 
MRI has been shown to improve overall survival in patients with hereditary breast 
cancer syndromes (35-37). Recent approaches allow for one to visualize tumor 
physiology in addition to tumor anatomy. For example, diffusion-weighted MRI uses the 
slow diffusion of water molecules in tumors to generate contrast (38). Moreover, the use 
of contrast agents can allow for the detection of tissue vascularization, and iron oxide 
nanoparticles can be conjugated with targeting molecules to serve as direct imaging 
probes (39-41). Despite its wide applications, MRI has significant limitations. The 
strength of the magnetic field precludes the use of MRI in patients with metallic 
instruments, such as pacemakers; cancer diagnosis can be hampered the presence of 
air or calcifications; and benign and malignant disease are difficult to distinguish on MRI 
alone (42). This has led to the recent introduction of scanners combing PET and MRI.  
  
4 
In US imaging, a transducer is used to generate sound pulses that propagate 
through tissue and are reflected back based on tissue density (43). US is commonly 
used for cancer detection and to aid in the collection of biopsy samples. The main 
benefits of US imaging, compared to other imaging techniques used in oncology, are its 
low cost, portability, and its ability to collect imaging data in real-time, which makes it 
ideal for repeated measurements (44, 45). When used with specialized probes such as 
microbubbles, US is able to provide information regarding tumor vasculature in addition 
to anatomic data (46). Major limitations of US include poor penetration into bone, 
disruption of sound waves by air or gas, and difficulty in imaging obese patients (47).  
The focus of this thesis is the use of PET imaging. PET is a functional imaging 
technique that uses positron-emitting radionuclides to monitor specific physiologic 
processes. As the radionuclide decays, it emits a positron, which collides with an 
electron, resulting in the annihilation of both particles and the production of a pair of 
gamma photons, which are subsequently detected by the scanning device (48, 49).  
PET can be used to generate either static or dynamic images. In static PET, data is 
acquired at a single time point after the injection of a tracer and is used to generate a 
single frame that represents the average amount of radioactivity during the scan period. 
Tracer uptake in tissue is frequently expressed using the semi-quantitative 
measurement Standardized Uptake Value (SUV), which corresponds to the amount of 
radioactivity in the tissue divided by the injected dose per bodyweight (50). By contrast, 
in dynamic PET, images collection starts immediately after tracer injection, and tracer 
activity is monitored over time using a series of continuous acquisitions. Dynamic PET 
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enables the generation of time-activity curves of the tissue concentration of the 
radiotracer allowing for the measurement of its pharmacokinetic properties (51).  
Classically, PET has been conducted using 18F-FDG, which allows for the 
detection of malignancies due to increased glucose metabolism compared to normal 
tissue (17-19). 18F-FDG PET is indicated for the diagnosis and staging of several 
neoplasms including breast, lung, and gastrointestinal cancers, and is now used to 
adjust treatment in lymphoma (52-57). Additionally, the use of PET has been explored 
as a tool for breast cancer screening (58-61). A limitation of 18F-FDG is that non-specific 
tracer uptake in reactive lymph nodes or infiltrating macrophages can lead to false-
positive results (62, 63). Newer approaches using different small molecules, as well as 
radiolabeled peptides, nanoparticles, and antibodies, allow for the assessment of a 
variety of cellular receptors and pathways (64-68). In addition, several radionuclides 
have been explored, such 11C, 13N, 15O, 18F, 64Cu, 68Ga, 82Rb, and 89Zr, with half-lives 
ranging from 1.3 minutes (82Rb) to 3.3 days (89Zr) (69-74). Although it provides excellent 
functional information, the major weakness of PET is poor spatial resolution.  
Each of these imaging modalities has distinct set of advantages and 
disadvantages. Combined multimodal imaging enables the visualization of both tumor 
structure and biological processes at the molecular level, allowing for greater 
personalization of cancer therapy. For example, in patients with stage III lung cancer, 
for example, combined PET/CT can be used to detect residual cancer in mediastinal 
lymph nodes following chemotherapy, allowing physicians to determine which patients 
are eligible for surgical resection (75, 76). For that reason, imaging plays a prominent 
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role in several facets of modern cancer care: screening, diagnosis, and assessment of 
treatment response.  
Monitoring tumor proliferation 
Given that one of the defining characteristics of cancer is uncontrolled cellular 
proliferation, it is critical to develop methods to measure the proliferative capacity of 
tumors. Assessments of tumor proliferation have been found to have prognostic value 
and have been incorporated into tumor grading systems (77-79). Several techniques 
have been developed to monitor tumor proliferation, including analysis of fixed tissue as 
well as imaging approaches.  
One of the first methods for measuring tumor aggressiveness was mitotic index 
(MI), which refers to the proportion of cells undergoing mitosis in a tumor specimen, and 
is expressed as mitotic bodies per high-power field-of-view (80). MI relies on 
inexpensive and simple tissue processing methods, and has been shown to predict 
survival in breast cancer (77, 81). However, poor tissue processing, inaccurate 
counting, and difficulty in identifying mitotic cells has led to concerns over the 
reproducibility of MI (82). Moreover, because of variability in the duration of mitosis, the 
number of mitotic bodies and the rate of cell proliferation may not be correlated (83). 
Rates of proliferation can be more effectively determined by measuring the fraction of 
cells in the S-phase of the cell cycle (SPF) using techniques such as flow cytometry to 
measure the phase distribution of cells, 3H-thymidine labeling, or incorporation of 5-
bromodeoxyuridine into DNA (84-86).  
The most common current method for measuring proliferation in patient samples 
is the Ki-67 labeling index. Ki-67 is a nuclear protein expressed in cells in the G1, S, G2, 
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and M phases, but not in resting (G0) cells (87-89). Staining of tumor specimens with 
antibodies directed against Ki-67 can be used to measure the percentage of 
proliferating tumor cells. While its exact function remains unknown, Ki-67 has been 
shown to be a robust biomarker for tumor aggressiveness, correlating with tumor 
recurrence and poor prognosis in numerous studies (90-93).  
The major weakness of these approaches to assessing tumor proliferation is that 
they require a biopsy samples, or repeated biopsies in order to gauge treatment 
response. For many malignancies, the transition from a single progenitor cell to 
detectable mass takes several years (94). During this time, distinct tumor 
microenvironments form, in which cells are exposed to different environmental 
stressors, and have access to different levels of nutrients and growth factors (95-97). 
The result is significant intratumoral genetic heterogeneity (98, 99). Hence, small biopsy 
specimens used assess proliferation may not provide an accurate sample from a large 
tumor mass. Furthermore, they do not provide information with regards to metastatic 
foci in patients with advanced disease (100).  
The shortcomings of biopsy-based metrics have led many to pursue the use of 
imaging. Studies comparing tumor uptake of FDG and cell proliferation rate showed 
some promise, but ultimately yielded mixed results (101, 102). Early attempts to image 
DNA replication, and thus cellular proliferation, involved the use of 11C-labeled 
thymidine (TdR) (103). 11C-TdR was found to be retained by tumors and other 
proliferating tissues, and incorporated into DNA (104). Several studies have evaluated 
the use of 11C-TdR in human cancers, with one study finding a reduction in tracer 
uptake after chemotherapy to be predictive of clinical treatment response (105). 
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However, logistical challenges such as the short half-life of 11C (20.3 minutes), difficult 
synthesis, and rapid degradation in vivo by plasma and cytosolic thymidine 
phosphorylase (TP), ultimately prevented regular clinical use of 11C-TdR (106, 107).  
18F-FLT PET 
Imaging with 3’-deoxy-3’-fluorothymidine (FLT) was developed to address the 
drawbacks of imaging with 11C-TdR (108). FLT was originally introduced as an anti-
neoplastic agent due to its inhibition of DNA synthesis via chain termination (109). It 
was later found to be an effective anti-viral compound and used in the treatment of HIV, 
following the success of a similar drug, 3’-azidothymidine (AZT) (110, 111). However, 
unacceptable hematologic and hepatic toxicity halted the clinical use of FLT. Although 
toxic at therapeutic doses, imaging studies typically use less than 1% of a single clinical 
dose of FLT, and therefore toxicity is not a concern. The structure of FLT is nearly 
identical to TdR, except that fluorine has been substituted for the hydroxyl group at the 
3’ position of the sugar, which increases the in vivo stability of FLT compared to TdR 
(Figure 1.1). As a PET tracer, FLT can be labeled with 18F instead of 11C, which greatly 
improves tracer half-life and therefore makes clinical use more feasible.  
Cellular uptake and retention of FLT follows the TdR salvage pathway. FLT 
enters the cell via human nucleoside transports 1 and 2 (hENT1 and hENT2), human 
concentrative nucleoside transporter (hCNT), as well as passive diffusion (112, 113) 
(Figure 1.2). Phosphorylation by the thymidine kinase 1 (TK1) leads to the intracellular 
trapping of FLT, primarily as FLT-monophosphate (FLT-MP) (114, 115). FLT is subject 
to glucuronidation in the liver followed by renal excretion in humans (116-118). Early 
studies conducted in humans and dogs noted that FLT accumulates in proliferative 
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tissues (e. g. bone marrow, tumors) and has been found to be strongly correlated with 
Ki-67 (108, 119). 
It should be noted that cells have two ways of obtaining TdR for DNA synthesis: 
the previously described salvage pathway, and the de novo pathway, in which the 
enzyme thymidylate synthase (TS) catalyzes the methylation of deoxyuridine 
monophosphate (dUMP) to TdR-monophosphate (TMP) (120). Broadly speaking, the 
balance of de novo TdR synthesis and TdR salvage determines the rate of FLT 
retention within an individual cell (121, 122). Tumors more reliant on salvage will be FLT 
avid, whereas tumors that primarily utilize de novo TdR biosynthesis will exhibit low 
tracer retention, irrespective of their proliferative capacity (123).  
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TdR 
FLT FMAU FAU 
Figure 1.1: Thymidine and related PET tracers. TdR can be labeled at the methyl 
and ring-2 position with 11C. Analogues of TdR can be labeled with 18F in the 3’ or 2’ 
position of the ribose, and are resistant to cleavage by TP. FMAU and FAU can be 
incorporated into DNA after phosphorylation by TK1. Due to the lack of a 3’ hydroxyl 
group, FLT functions as a chain terminator when incorporated into DNA.  
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TdR 
FLT 
hENT1 
 
hCNT 
 
Passive 
Diffu
s
i on 
TdR TMP 
DNA 
Synthesis 
dUMP 
TTP 
TS 
de novo  
pathway 
Thymidine Salvage Pathway 
TK1 
TDP 
FLT FLT-MP FLT-TP FLT-DP 
Figure 1.2: Thymidine pathways used for DNA synthesis. In the salvage pathway, 
TdR and FLT enter the cell via nucleoside transporters (primarily hENT1) and diffusion. 
Inside the cell, TdR and FLT are phosphorylated by the ATP-dependent enzyme TK1 to 
TdR-monophosphate (TMP) and FLT-monophosphate (FLT-MP), respectively. TdR is 
further phosphorylated to TdR-diphosphate (TDP) and TdR-triphosphate (TTP) and then 
incorporated into DNA. Similarly, FLT-MP can be further phosphorylated into FLT-
diphosphate (FLT-DP) and FLT-triphosphate (FLT-TP), but causes chain termination if 
incorporated into DNA. Alternatively, cells can obtain TdR using the de novo pathway, in 
which TS methylates deoxyuridine monophosphate (dUMP) to TMP.  
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Within the TdR salvage pathway, several factors impact FLT uptake. Expression 
of FLT transporters, especially hENT1, has been shown to have profound impact on 
tumor FLT accumulation. Tumors with low hENT1 activity, either due to natural tumor 
physiology or inhibition, exhibit poor retention of FLT despite normal TK1 function (124, 
125). Moreover, studies incorporating autoradiography and immunohistochemistry (IHC) 
have shown a strong correlation between expression of hENT1 and FLT retention (126). 
High endogenous TdR levels, such as found in rodents, can interfere with tracer 
retention by competing with FLT both at the level of nucleoside transporters as well as 
intracellular enzymes, resulting in low FLT retention despite proliferative tumors (127, 
128). Moreover, some anti-cancer treatments may cause changes in circulating TdR 
(129). Likewise, high expression of TP in tumors has been shown to correlate with 
increased FLT accumulation in both preclinical models and patient biopsies (130, 131). 
The primary determinant of cellular uptake of FLT is TK1 activity (132). TK1 is a 
cytosolic enzyme that catalyzes the transfer of a phosphate group from ATP to the 5’ 
hydroxyl group of TdR to form TMP, and plays a key role in regulating intracellular TdR 
pools (133). Activity of TK1 is highly dependent on the growth state and phase of the 
cell cycle. The enzyme is up-regulated 10-fold during the S-phase of the cell cycle, and 
is low or absent in quiescent cells (134-136). Several studies across a wide range of cell 
lines and human xenografts have demonstrated a strong correlation between FLT 
retention and TK1 protein expression (137-140). In addition to protein levels, other 
factors related to TK1 activity, and therefore FLT uptake, have been elucidated. ATP is 
a required cofactor for the enzymatic activity of TK1, and kinetic analyses in glioma and 
fibrosarcoma have underscored the importance of ATP in FLT accumulation (141, 142). 
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Lastly, post-translational modification of TK1, specifically phosphorylation of serine 
residues, has also been shown to augment TK1 activity (143).  
Imaging response to therapy with 18F-FLT 
 Since its inception, 18F-FLT has been used to examine the response of cancer to 
a variety of treatments such as chemotherapy, targeted agents, radiation, and 
endocrine treatment, among others. This review will focus on the use of FLT to monitor 
the effects of cytotoxic chemotherapy, which has undergone extensive research. 
Akylating agents such as temozolamide and cyclophosphamide produce a decrease in 
18F-FLT uptake that is in line with decreases in Ki-67 in preclinical models of glioma and 
lymphoma (144, 145). Similarly, in patients with non-Hodgkin lymphoma treated with 
cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone, 18F-FLT was 
markedly decreased 7 days after the start of therapy (146). A decrease in 18F-FLT 
uptake following treatment with the anthracycline doxorubicin has been found to predict 
response in preclinical models of lymphoma, lung cancer, and hepatoma (147-149). 
Furthermore, 18F-FLT is now being investigated as a way to assess response in patients 
with acute myeloid leukemia being treated with a related compound, idarubicin (150). In 
addition, post-treatment reductions in 18F-FLT retention have been shown to be 
predictive of response to cisplatin in patient-derived models of ovarian cancer (151). 
 Unlike the previous described treatments, which cause reductions in 18F-FLT 
uptake as cells lose their proliferative capacity, agents that target the de novo TdR 
synthesis pathway, such as the TS-inhibitor 5-fluorouracil (5-FU), can lead to a transient 
rise in FLT uptake, termed the ‘flare’ phenomenon (152).  As TMP levels drop due to TS 
inhibition, TdR salvage proteins, TK1 and hENT1, are upregulated, as cells attempt to 
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replenish TMP levels exogenously (126, 152, 153). This increase in TdR salvage leads 
to a window of 1-24 hours in which FLT uptake is increased until insufficient TMP 
results in arrest of DNA synthesis and cell death. This effect has been observed in 
response to nucleoside analogs: 5-FU and gemcitabine, as well as antifolates: 
methotrexate and pemetrexed (Pem) in preclinical models of glioma, esophageal, colon, 
and breast cancer (142, 152, 154-157). The flare has been explored as a marker for 
treatment response in a trial of colorectal cancer patients treated with 5-FU as well as a 
study of Pem in non-small cell lung cancer (NSCLC) patients. In both of these studies, 
the presence of a flare shortly after therapy did not correlate with response (158, 159). 
Of note, the results observed by Frings et al. may have been confounded by the use of 
steroids, which will be expounded upon later. As of now it remains unclear if the flare 
effect can be a useful tool for assessing response. It may simply be a way to indicate 
that the drugs are hitting their targets.  
Limitations of 18F-FLT PET 
 Despite its promise as a proliferation imaging agent, 18F-FLT has a number of 
noteworthy limitations. High basal uptake in normal bone marrow and excretory organs 
(liver, kidneys, bladder) restrict the use of 18F-FLT in cancers involving those regions 
(160). As discussed, 18F-FLT uptake will underestimate cell proliferation in tumors that 
are heavily reliant on de novo TdR synthesis (121). Moreover, treatments that alter the 
balance between the de novo and salvage pathways such as TS-inhibiting agents, anti-
folates, or topoisomerase inhibitors can have drastic effects on tumor 18F-FLT retention, 
which may not reflect changes in proliferation (142, 152, 155, 161). Finally, similar to 
what has been observed with FDG, inflammation can be a source of confusion when 
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imaging with 18F-FLT. Previous work has illustrated that proliferating macrophages due 
to bacterial infection or atherosclerosis exhibit significant uptake of 18F-FLT (162, 163). 
In trials examining FLT uptake in patients with head and neck cancers, high tracer 
uptake in proliferating lymphocytes within lymph nodes resulted in false-positive findings 
(164, 165).  
Other fluoropyrimidine tracers  
 The success of FLT spurred the development of other fluoropyrimidine PET 
tracers. Like FLT, 1-(2’-deoxy-2’-fluoro-β-D-arabinofuranosyl) thymidine (FMAU) was 
developed as an anti-viral and anti-neoplastic compound due to cytotoxicity following its 
incorporation into DNA, but was later abandoned due to severe toxicity (166, 167). 
FMAU was later adapted to molecular imaging (160, 168). Like FLT, FMAU is resistant 
to TP-mediated cleavage due to the presence of fluorine on its ribose group. A key 
difference between the tracers, however, is that FMAU has an intact 3’ hydroxyl group 
and can therefore incorporate into the DNA (Figure 1.1) (169). Furthermore, FMAU is a 
more potent substrate for thymidine kinase 2 (TK2), located in the mitochondria, than 
TK1 (167). Unlike TK1, TK2 is constitutively expressed, with low activity in both dividing 
and quiescent cells (170, 171). Accumulation of 18F-FMAU is higher in tumors than most 
healthy tissues and preclinical studies have shown that its uptake is enhanced in 
response to conditions that produce an increase in mitochondrial mass such as 
oxidative, reductive, and energy stress (172, 173). In addition, low physiologic uptake of 
18F-FMAU by normal bone marrow may allow it to be useful in the detection and 
monitoring of bone marrow metastases (168). Further, the rapid clearance of 18F-FMAU 
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from the blood in humans (90% cleared within 10 minutes), allows for improved imaging 
in the pelvis compared to 18F-FLT and shortened imaging time (168, 174).  
1-(2’-deoxy-2’-fluoro-β-D-arabinofuranosyl) uracil (FAU) is a nucleoside analog 
that functions as a prodrug formm of FMAU (169). Following cellular uptake of FAU, it is 
phosphorylated to FAU monophosphate (FAU-MP) and then converted to FMAU 
monophosphate (FMAU-MP) via the action of TK1 and TS, respectively (175). FMAU-
MP is then incorporated into DNA, resulting in cell death (176). Dependence on TS for 
activation was designed to target FAU against malignancies with high expression of this 
enzyme and to avoid the neurotoxicity that resulted in the discontinuation of clinical 
FMAU use (166, 177-179). High expression of TS is a major mechanism of resistance 
to chemotherapeutic agents such as 5-FU and capecitabine and has been associated 
with poor clinical outcome in breast and colorectal cancer (180-182). Furthermore, the 
structure of FAU allowed for its tissue distribution to be monitored using PET, and 
potentially serve as a technique for imaging the de novo TdR synthesis pathway (183, 
184) (Figure 1.1). Early studies found that FAU caused significant growth inhibition 
when administered to cell models with high TS expression, and animal experiments 
showed incorporation of FAU into tumor DNA as FMAU (169, 179). However, the 
exploration of a FAU as a chemotherapeutic was later stopped when a patient 
developed fatal liver toxicity during a phase I clinical trial (185). However, a study of 18F-
labeled FAU in humans and dogs found higher uptake in tumors than normal tissue 
(177, 178). More recently, a pharmacokinetic modeling study demonstrated that the 
conversion of FAU to FMAU is greatly increased in tumors compared to normal tissues 
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(186). Therefore, its failures as a cancer treatment, FAU may have some utility as an 
imaging agent. 
Glucocorticoids and their use in cancer 
Glucocorticoids (GCs) are a class of steroid hormones that play a critical role in 
basal and stress-related homeostasis through their regulation of pathways involved in 
metabolism, cell proliferation and apoptosis, and inflammation (187-189). GCs comprise 
both endogenously produced cortisol, as well as a number of synthetic derivatives such 
as prednisone and dexamethasone (Dex). The actions of GCs are mediated by the 
glucocorticoid receptor (GR), a member of the nuclear receptor family of ligand-
dependent transcription factors. Alternative splicing of the human GR gene yields two 
isoforms with distinct functions: GRα and GRβ (190, 191). In the absence of hormone, 
GRα is located in the cytoplasm bound to a complex of chaperone proteins, including 
hsp90 (192). GC binding causes leads to the dissociation of GRα from its complex and 
subsequent translocation into the nucleus (193). In the nucleus, GRα homodimerizes 
and binds to Glucocorticoid Response Elements (GREs) where it has variable effects on 
the expression of target genes, depending on the specific promoter and GRE sequence 
(194). GRα can also exert GRE-independent effects on gene expression by interacting 
with transcription factors such as nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) and activator protein 1 (AP-1) (195, 196). Conversely, GRβ resides in 
the nucleus, is unaffected by the presence of hormone, and is not transcriptionally 
active (197). Rather, GRβ binds to GRα and prevents GRα-mediated transcriptional 
effects. Unlike GRα which is ubiquitously expressed, GRβ is expressed highly in 
specific tissues such bronchiole epithelium, liver bile ducts, and the thymus (198). The 
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ratio of GRα: GRβ in a given cell determines its sensitivity to GCs and contributes to the 
variability of their effects across different tissues (199).  
GCs are standard-of-care treatments in several lymphoid malignancies including 
acute lymphoblastic leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple 
myeloma (200-204). In these cell types GR signaling leads to apoptosis (205, 206). The 
precise mechanism of GC-mediated apoptosis remains unclear, but may be due to 
induction of pro-apoptotic members of the Bcl-2 family and/or inhibition of anti-apoptotic 
proteins (187, 207).   
Unlike in cancers of hematopoietic cells, GCs do not typically cause apoptosis in 
solid tumors (208). However, GCs such as Dex have been found to exert an anti-
proliferative effect in several cancer models through reversible G1 cell cycle arrest (209-
211). Following the removal of Dex, cells reenter the cell cycle in a synchronized 
fashion, with an enrichment of cells in the S-phase after 24 to 48 hours (210, 212, 213). 
Growth inhibition by Dex occurs in only in tumors with high expression of GR and can 
be blocked by the GR antagonist RU-486 (214-216). High GR expression has been 
observed in many tumors such as breast, lung, renal, glioma, and melanoma, reflecting 
its wide distribution in healthy tissues (217, 218).  
Given that many chemotherapeutic agents have been found to be most 
efficacious when applied to rapidly growing cells, and that radiation sensitivity varies by 
cell cycle, many studies have sought to examine the effect of Dex on the effectiveness 
on these cytotoxic treatments (219, 220). In both cell models and xenografts GC 
pretreatment has been demonstrated to reduce the therapeutic effect of commonly used 
agents such as including cisplatin, doxorubicin, methotrexate, and Pem (213, 221-224). 
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A large randomized trial in breast cancer patients found that the addition of low-dose 
prednisone to standard adjuvant chemotherapy resulted in no survival benefit and was 
associated with increased risk for bone relapses (225). Additionally, a retrospective 
study of teniposide in NSCLC patients with brain metastases found that patients who 
received GCs for peritumoral edema had a significantly lower response rate than 
patients who did not receive GCs (226). However, patients receiving GCs may have 
simply had more severe disease. Further research is likely required to determine if 
chemoprotective effects of GCs observed in cancer models extend into human disease. 
For patients with solid tumors, GCs are most commonly used to provide 
symptomatic improvements such as relief of fever, weakness, and lethargy. GCs can 
also produce a feeling of mild euphoria and stimulation of appetite in critically ill patients 
(227, 228). In patients with brain tumors, daily Dex treatment is used to reduce edema 
that responsible for neurologic symptoms (229). GCs are also used to improve side 
effects associated with chemotherapy. Dex is routinely used to reduce chemotherapy-
induced emesis (230). Pem, a standard therapy in advanced non-squamous NSCLC 
requires Dex prophylaxis to reduce the incidence and severity of a serious skin rash 
associated with its therapy (231).  
In summary, there is a lot of evidence in the literature that GCs can have 
detrimental effects on many anticancer drugs used to treat solid tumors, and that these 
effects are mediated through GR. However, it is not advisable to completely abolish 
their use given that 1) they play a vital role in the supportive care of cancer patients and 
2) not all tumors express GR at sufficient levels to elicit cell cycle arrest. A better option 
would be to explore the use of biomarkers to predict which patients would benefit from 
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GCs, and in which patients they should be avoided. In this dissertation I will explore the 
use of FLT-PET as such a biomarker.  
I have the following specific aims: 
1) Utilize FLT to detect Dex-mediated S-phase suppression in NSCLC cell lines, 
xenograft models, and in patients.   
2) Examine a flare in TK1 activity following Pem treatment in NSCLC, and assess 
its utility as a marker for Dex suppression in NSCLC.  
3) Explore the effects of capecitabine treatment on the uptake of fluoropyrimidine 
PET imaging agents.  
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CHAPTER 2 UTILIZING FLT UPTAKE TO MONITOR THE EFFECT OF 
DEXAMETHASONE ON NON-SMALL CELL LUNG CANCER 
 
BACKGROUND 
 Lung cancer is the leading cause of cancer-related mortality in the United States, 
accounting for 27% of cancer deaths (4). NSCLC comprises 83% of lung cancers, and 
the majority of patients have advanced disease at the time of diagnosis (232). Several 
randomized clinical trials have shown that Pem, given as a monotherapy or in 
combination with a platinum-containing compound, is preferred chemotherapy for the 
treatment of advanced non-squamous NSCLC (233-236). Pem is a folate anti-
metabolite that enters cells via the reduced folate carrier (RFC) and the proton-coupled 
folate transporter (PCFT), and causes cytotoxicity through inhibition of TS, as well as 
other enzymes involved in nucleotide biosynthesis including dihydrofolate reductase 
(DHFR) (237, 238).  
 Despite its relatively mild toxicity profile, a major adverse effect of Pem is the 
manifestation of a generalized, painful, pruritic skin rash (239). To protect against this 
rash, patients are administered 4 mg of Dex twice daily starting the day before therapy 
and continuing until the day after treatment (240). In addition, Dex is frequently used as 
an anti-emetic for patients receiving cisplatin or carboplatin (241). Dex is a synthetic GC 
that upon binding to GRα modulates genes involved in cell proliferation and apoptosis, 
as well as inflammation and the inflammatory response (242, 243). Recently, Dex, in a 
GRα-dependent fashion, has been found to cause reversible G1 cell cycle arrest in 
NSCLC cells, resulting in the protection of cells from Pem cytotoxicity (224).  
 Given that Pem is always accompanied by Dex pretreatment, chemotherapy with 
Pem may be contraindicated in subpopulation of tumors that are arrested when 
  
22 
exposed to the GC. It is therefore critical to develop a technique that can be used to 
ascertain the GRα level in patients who are candidates for Pem therapy. Analysis of 
biopsy specimens is likely inadequate for this task given the enormous clonal 
heterogeneity that has been observed within solid tumors and between metastatic foci 
(99, 100, 244). Furthermore, just the presence of GRα in a tumor may not indicate that 
the pathway is actually functional.  
 A rapid and non-invasive technique to functionally image the effect of Dex on 
NSCLC over a patient’s entire cancer burden would be to monitor retention of 18F-FLT. 
Developed for use with PET, radiolabeled FLT is taken up by tumor cells and trapped 
intracellularly via phosphorylation by the S-phase-specific enzyme TK1 (245). Changes 
in 18F-FLT retention can therefore be used to monitor the effect of compounds such as 
Dex which alter cell cycle progression (108). Uptake of 18F-FLT is reproducible and has 
been shown to correlate with the proliferative marker Ki-67 in NSCLC (119, 160, 246). 
Here we applied 18F-FLT PET is as a direct functional probe to measure Dex-mediated 
S-phase suppression in NSCLC. Additionally, we sought to use 18F-FLT accumulation to 
monitor the effect of Pem in vivo. The basis for this was the observation that 
compounds that inhibit de novo TdR biosynthesis, such as Pem, elicit a transient 
increase in FLT uptake due to up-regulation of TdR salvage, termed the ‘flare’ 
phenomenon (154, 155). This effect may provide a way to visualize the interference of 
Dex with Pem activity in vivo.    
MATERIALS AND METHODS 
Cell culture and reagents  
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Non-squamous NSCLC cell lines A549, H1299, H358, H226, H460, H1650, and 
H292 were grown in RPMI 1640 medium (GE Life Sciences), supplemented with 10% 
fetal bovine serum (FBS) (Life Technologies, Carlsbad, CA), 1% penicillin and 
streptomycin and 2mM glutamine (GE Life Sciences) in a humidified incubator at 5% 
CO2 and 37°C. H1299 cells over expressing GRα (H1299-GRα) were a generous gift 
from Dr. Manohar Ratnam at the Karmanos Cancer Institute; their development is 
described elsewhere (224). All Cell lines were authenticated using the PowerPlex(r) 16 
System from Promega (Madison, WI) in the Applied Genomics Technology Center at 
Wayne State University.  Sample collection and analyses are performed in the 
Biobanking and Correlative Sciences using ATCC and DSMZ reported karyotypes.  The 
method requires a match of over 80% for a cell line to pass authentication and all the 
cell lines used had a 100% match (247). Charcoal-stripped FBS was purchased from 
Life Technologies to remove glucocorticoids. Dexamethasone used in cell studies was 
purchased from EMD Millipore (Billerica, MA) and Pemetrexed was obtained from LC 
Laboratories (Woburn, MA). Veterinary grade dexamethasone (Dexaject) was 
purchased from Bimeda (Llangefni, Wales, UK). PCR primers and TaqMan probes were 
either purchased from the Life Technologies inventory or custom synthesized by 
Integrated DNA Technologies (Coralville, IA). The anti-GR antibody (#12041) used in 
western blot and immunohistochemistry analysis was purchased from Cell Signaling 
Technology (Danvers MA).  
3H-FLT uptake measurements 
  Cells were seeded 5 x 105 cells/well in a 6-well plates in phenol-red-free medium 
supplemented with charcoal-stripped FBS. Treatments were initiated after the cells were 
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attached. After the pre-specified treatments, cells were transferred to media containing 
approximately 1600 Bq 3H-FLT (95% pure by high performance liquid chromatography 
(HPLC)) obtained from Moravek Biochemicals (Brea, CA) and incubated for 1 hour. 
Media was then removed and cells were washed four times with ice cold phosphate-
buffered saline (PBS) (Life Technologies) to remove radioactive media. After washing, 
cells were lysed by 1M KOH, mixed with 5 mL of Ultima Gold XR scintillation cocktail 
(PerkinElmer, Waltham, MA) and sample activity was measured by a Packard Tricarb 
2910TR liquid scintillation analyzer (PerkinElmer, Waltham, MA). Activity of samples 
was normalized to cell number using a parallel experiment and cell counting via the 
trypan blue (Invitrogen, Carlsbad, CA) exclusion method. All experiments were 
performed in triplicates.  
Establishment of NSCLC xenografts  
The Wayne State University Institutional Animal Care and Use Committee 
approved all experimental procedures described herein. Subcutaneous tumor 
xenografts were established by implanting cubic fragments (~2 by 2 by 2 mm) of tumor 
tissue bilaterally into the axilla of 4-6 week old female SCID NCr mice purchased from 
Charles River Laboratories (Wilmington, MA) using a 12-gauge trocar. Mice were 
supplied water and food ad libitum. It is important to note that compared to humans, 
mice have 10-fold higher plasma levels of folates, predominantly levomefolic acid, which 
has been shown to reduce the activity of anti-folates such as Pem and raltitrexed (248, 
249). In addition, there is a 10-fold higher level of TdR in murine plasma compared to 
human plasma, which represents a significant issue for the testing of TS inhibitors, such 
as PEM, in mice (250, 251). Circulating TdR can be taken up by cancer cells and 
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converted to TMP thereby rescuing TdR depletion caused by inhibition of TS (252). 
These two issues may complicate study of the anti-folate and TS inhibitor Pem in 
murine models. Feeding animals a folate-deficient diet has been shown to reduce 
endogenous folate levels and simulate drug toxicity observed in humans (253). 
Therefore, animals treated with Pem were placed on a low-folate diet (Harlan Teklad, 
Madison, WI) starting 10 days prior to treatment. Tumor measurements were made 
twice per week using calipers and tumor volumes were calculated by the formula, V = (L 
x W2)/2, where (L) is the longest diameter and width (W) is the shortest diameter. 
Animals were placed on study when tumors reached an average volume of 250 mm3. 
MicroPET imaging 
PET images were acquired using a Concorde Microsystems R4 scanner 
(Knoxville, TN). Animals were injected intravenously (iv) with approximately 9.5 MBq of 
18F-FLT, synthesized as published (254). One hour following tracer injection, anesthesia 
was induced in mice with 3% and maintained 2% isofluorine for the duration of the 
experiment. Anesthetized mice were placed supine in the microPET scanner and 
positioned such that their tumors would near to the center of the field of view. During the 
10-minute emission scan, animals’ body temperature was maintained by a heating 
component under scanner bed. After their final scan, animals were euthanized while still 
under anesthesia via cervical dislocation, or if they had recovered from anesthesia, they 
were euthanized with CO2 followed by cervical dislocation. Reconstructed images were 
evaluated with PMOD imaging software (Zurich, Switzerland) and tumor borders were 
defined with isocontours halfway between the minimum and maximum thresholds of the 
tumor. Tracer activity within these regions was corrected for decay and converted to 
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standardized uptake values (SUVs), using the formula SUV = [Radioactivity 
concentration in Tumor (kBq/cc) / Injected Dose (kBq) / Body Weight (g)]. Data is 
expressed in terms of SUVmax, which reflects the activity of the hottest pixel within the 
tumor.  
Measurement of Dex levels in animal blood 
 Whole blood was collected from animals treated with Dex at pre-determined 
intervals via cardiac puncture. Serum was collected by allowing whole blood to clot at 
room temperature for 30 minutes, followed by refrigerated (4°C) centrifugation at 10,000 
x g for 15 minutes to remove the clot. The resultant serum samples were stored at -
20°C.  Serum Dex concentration was then measured with LCMS/MS analysis following 
published protocols (255).  
Tissue preparation and IHC  
 Animal tumors were removed and fixed in 10% neutral-buffered formalin (Fisher 
Scientific, Pittsburgh, PA) at room temperature for 48 hours. Specimens were then 
dehydrated with ethanol and embedded into paraffin blocks. Blocks were divided into 5 
µM sections using a microtome and transferred onto glass slides. For IHC, paraffin was 
removed from tissue sections and antigens were retrieved by heating-induced epitope 
retrieval. Sections were incubated for 1 hour at room temperature with 10% goat serum 
in PBS to decrease non-specific binding and incubated overnight at 4°C with rabbit anti-
GR (1:400). Samples were counterstained with Meyer’s hematoxylin (Lab Vision, 
Fremont, CA).  
Patient imaging 
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Four patients recently diagnosed with advanced non-squamous NSCLC were 
enrolled at the Karmanos Cancer Center. Patients were selected because they were 
scheduled to receive Dex alongside chemotherapy with Pem or docetaxel. Patients 
were imaged with 18F-FLT PET at baseline and after treatment with oral Dex (4 mg 
twice daily) for 24 hours. 18F-FLT was synthesized as described previously, and injected 
iv into patients (range: 167-265 MBq; mean: 226 MBq) over 60 seconds. Following an 
incubation period of 1 hour, static, whole body PET and CT images were collected using 
a GE Discovery STE PET/CT scanner (GE Medical Systems, Milwaukee, WI). 
Reconstructed images were viewed using Osirix Imaging Software (Geneva, 
Switzerland). Tumor SUVmax values were obtained by drawing volumes of interest over 
the tumor plane with the most active pixel and the two adjacent planes. In patients with 
multiple lesions, all evaluable (> 2 cm) lesions were assessed using this technique. The 
protocol for this study was reviewed and approved by the institutional review board at 
Wayne State University. All patients signed a written informed consent prior to their 
enrollment.  
Statistical considerations 
All statistical tests were conducted using GraphPad Prism version 6 (GraphPad 
Software, La Jolla, California, USA). For cellular tracer uptake studies, one-way ANOVA 
analysis was used. For animal studies we utilized paired sample ANOVA analysis 
adjusting for unequal sample size, when appropriate.  
RESULTS  
  
Changes in 3H-FLT uptake reflect sensitivity to Dex  
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As discussed, the level of expression of GRα was found to be the major factor in 
determining whether cells would be protected from Pem following Dex pretreatment. To 
determine whether Dex sensitivity is associated with changes in FLT uptake, several 
NSCLC cell lines with varying expression of GRα were tested, including A549, H292, 
H226, H358, H460, H1650, H1299, and the recombinant cell line H1299-GRα (Figure 
2.1). Cells were plated in glucocorticoid-depleted media, and treated with Dex (100 nM), 
which corresponds to the peak plasma dose of Dex in humans following a single dose 4 
mg oral Dex (256). In cells with the highest relative GRα expression there was a 
significant reduction in 3H-FLT accumulation after 24 h Dex (Figure 2.2). 3H-FLT was 
further decreased after 48 h, in-line with observed suppression of the S-phase fraction 
of cells (P < 0.01).   
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Figure 2.1: GR expression in NSCLC cell lines. (A) GRα mRNA measured by RT-
PCR. Error bars represent standard deviation between biological triplicate samples (B) 
Western blot showing total GR protein expression.    
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Figure 2.2: Effect of Dex on 3H-FLT retention in NSCLC cell lines: NSCLC cell lines 
were grown in glucocorticoid-depleted media and treated with Dex (100 nM) or vehicle 
(ethanol) for 24 or 48 hours. Cells were then transferred to media containing 3H-FLT 
and incubated for 1 hour. After washing, cells were lysed by KOH and the activity of 
samples was measured with a liquid scintillation counter and normalized to vehicle. Cell 
lines with the highest relative levels of GRα exhibited significant reductions in 3H-FLT 
uptake after Dex treatment. In contrast, tracer uptake low-GRα expressing cells was 
unchanged by Dex. P < 0.01 
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Dex reversibly decreases 18F-FLT retention in human xenografts  
To determine whether 18F-FLT PET can detect Dex sensitivity in vivo, SCID mice 
were implanted bilaterally with A549 tumors and were treated and imaged according to 
the protocol shown in Figure 2.3. Dex dosing in animals was scheduled to simulate the 
dosing regimen used clinically, and serum Dex levels were verified using LCMS/MS 
(Table 2.1). A dosing system of 15 mg/kg, twice daily, intraperitoneally (ip) was found to 
produce steady state serum concentrations within the pharmacological effective range 
of Dex (~37 nM 12 hours after the 3rd dose) (257). SUVmax in A549 tumors decreased by 
an average of 63.1% following 24 h Dex (Figure 2.4). 72 h post treatment, tumors 
regained their proliferative capacity and SUVmax values were in-line with control 
tumors, indicating the reversibility of Dex-mediated cell cycle arrest P < 0.01.  
To further establish the ability of 18F-FLT to image the anti-proliferative effect of 
Dex, we imaged mice bearing low-GRα H1299 tumors as well as H1299 tumors in 
which GRα has been lentivirally transduced. Similar to animals with A549 tumors, mice 
bearing H1299-GRα exhibited post-treatment reductions in tumor SUVmax that 
rebounded after 72 h Dex withdrawal (Figure 2.4). Interestingly, in H1299 tumors, which 
express low levels of GRα and were unaffected by Dex in cell culture, we observed a 
mean decrease of 20.8% in FLT accumulation. Harvested tumors revealed that although 
GRα mRNA levels remain lower in H1299 tumors than the other xenograft models used 
herein, H1299 tumors stained positive for GR (Figure 2.5). This result is likely due to 
greater cellular stress (e.g. hypoxia) in tumor cells compared to H1299 cells grown in 
culture leading to an upregulation of GR (258).  
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Figure 2.3: Dex treatment and animal imaging protocol. 4-6 week-old female SCID 
mice were implanted with A549 or H1299 xenografts via trocar. After a period of tumor 
growth animals were imaged at baseline (Scan 1), after 24 h of treatment with Dex (15 
mg/kg twice daily, ip) or control (Scan 2), and again 72 h after the final treatment (Scan 
3) to assess reversibility.  
 
Table 2.1: Measurement of serum Dex at 
various time points. To validate our Dex 
dosing regimen, mice were treated (15 
mg/kg ip, twice daily) for 24 h (3 doses 
total). Blood samples were collected at 24 
hours (pre-dose), 26 h, 36 h, and 48 h. Two 
mice were used for each time point. Serum 
Dex spiked 2 h post treatment and settled to 
an average of 38 nM by 36 h. Dex levels 
were undetectable 24 h after the final dose.  
 
 
 
Sampling 
Time (Hr) 
Serum Dex 
Concentration 
(nM) 
24 (pre-dose) 22 
24 (pre-dose) 28 
26 4970 
26 8140 
36 61 
36 14 
48 0 
48 0 
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Control 
FLT 
PET 
Scan 2 
FLT 
PET 
Scan 3 
 
     
 
 
  
33 
 
Figure 2.4A: Representative 18F-FLT PET images of mice with A549 xenografts. In 
control animals (top panel) tumors exhibited negligible change in 18F-FLT uptake 
between the three scans.  In mice treated with Dex for 24 h (bottom panel), tumor 18F-
FLT retention decreased by 57.5 and 54.7. 72 h after the final dose of Dex, tumors 
returned to baseline levels of tracer uptake.  
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Figure 2.4B: 18F-FLT uptake in high-GRα A549 xenografts. SUVmax values of 
tumors treated with Dex (15 mg/kg bid, ip) (n = 9) or control (saline) (n = 11) at baseline, 
after 24 h treatment, and 72 h post-treatment. After 24 h Dex tumor 18F-FLT retention 
declined by an average of 63.1%. 72 h after the final dose of Dex, however, tumors 
return to control levels of tracer uptake. *P < 0.01 
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Figure 2.4C: 18F-FLT PET images of mice with H1299 xenografts. Animals were 
implanted bilaterally with either H1299 or H1299-GRα tumors. In animals with low-GRα 
H1299 tumors (top panel) 18F-FLT uptake decreased by 6.7% and 17.0% after 24 h 
Dex. In H1299-GRα tumors, 18F-FLT uptake decreased by 51.6% and 51.7%.  
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Figure 2.4D: 18F-FLT uptake in H1299 xenografts. Dot-plot comparing SUVmax values 
of H1299 (n = 15) tumors with H1299-GRα (n = 9) following 24 h Dex (15 mg/kg bid, ip) 
treatment. 18F-FLT uptake in H1299 tumors decreased by 20.8% versus in 41.3% 
H1299-GRα. Effects of Dex reversed 72 h after the final Dex treatment. P < 0.01.  
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Figure 2.5A: GRα mRNA in human xenografts. Tumors were harvested and GRα 
mRNA was measured by RT-PCR. Error bars represent standard deviation between 
biological triplicate samples.  
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Figure 2.5B: GR staining in human xenografts. Representative pictures of tumors 
stained with hematoxylin and eosin (left) or an anti-GR antibody. 
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18F-FLT PET visualizes interlesion heterogeneity in Dex sensitivity between 
metastases in human tumors 
 
To determine whether our findings in NSCLC cell lines and xenografts extend to 
human disease, we have extended our work into four patients with advanced NSCLC. 
Patients were imaged at baseline and again after 24 h of oral Dex treatment (4 mg bid) 
as is standard practice in patients receiving Pem chemotherapy.  After 24 h Dex, tumors 
in patients #1 and #3 demonstrated marked reductions in tumor SUVmax (-64.7% and -
54.3%, respectively). Conversely, patients #2 and #4 were largely unaffected by Dex 
treatment, highlighting variability in GRα expression in between individual cancers 
(Table 2.2). Furthermore, we observed marked heterogeneity within individual patients, 
as the lesions of patient #1 showed variable change in 18F-FLT uptake after Dex (Figure 
2.6). This finding demonstrates the value of imaging in this setting, as this may have 
gone unnoticed with a purely biopsy-based approach.  
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Figure 2.6: Interlesion heterogeneity in a NSCLC patient. 18F-FLT PET images from 
a patient with NSCLC at baseline (left) and after 24 h Dex (4 mg twice daily, left). In the 
lymph node metastasis indicated ‘A’ , 18F-FLT uptake decreased by 64.7% after 24 h 
Dex. However, as shown in the coronal reconstructions in the left panels, change in 18F-
FLT retention is highly variable between different nodal metastases. Tracer retention in 
lesions indicated by ‘B’, ‘C’, ‘D’, and ‘E’ decreased by 13.7%, 33.1%,18.1%, and 34.6% 
respectively.  
  
A A 
B 
C 
A 
E 
D 
B 
C 
A 
E 
D 
S
U
V
 
5
0
Baseline 24 h Dex 
A
x
ia
l 
C
o
ro
n
a
l 
  
41 
Patient Lesion 
Baseline 
(SUVmax) 
24 h Dex 
(SUVmax) 
% Change 
from 
Baseline 
1 
Primary Lesion 3.60 2.07 -42.6 
Lymph Node A 4.02 1.42 -64.7 
Lymph Node B 3.89 3.36 -13.7 
Lymph Node C 3.79 2.54 -33.1 
Lymph Node D 3.32 2.72 -18.1 
Lymph Node E 2.34 1.53 -34.4 
2 
Primary Lesion 8.42 7.22 -14.3 
Lymph Node A 5.74 4.60 -19.9 
Lymph Node B 5.18 5.04 -2.80 
3 
Primary Lesion 3.26 2.07 -36.4 
Lymph Node A 2.36 1.77 -25.1 
Lymph Node B 1.64 0.75 -54.3 
Lymph Node C 1.49 0.85 -42.8 
4 
Tumor A 2.08 1.85 -11.4 
Tumor B 4.00 3.43 -14.3 
Lymph Node A 6.13 6.83 11.5 
Lymph Node B 4.90 4.07 -17.0 
Lymph Node C 3.48 1.93 -44.6 
 
Table 2.2: Change in tumor 18F-FLT uptake in NSCLC patients after Dex. Patient #1 
and #3 displayed notable changes in 18F-FLT retention 24 h after Dex treatment, with 
differential changes between tumor lesions. In patients #2 and #4, changes in 18F-FLT 
uptake were less pronounced, highlighting the variability in sensitivity to Dex between 
patients. GRα expression is currently being assessed using IHC on fixed biopsy 
samples.   
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Dex abolishes Pem-mediated flare in 3H-FLT uptake in NSCLC cell lines 
As mentioned, compounds that interfere with de novo TdR biosynthesis, such as 
Pem, can lead to a temporary upregulation in TdR salvage, and therefore FLT 
accumulation, as cells seek to replenish intracellular TdR exogenously. Exploiting this 
phenomenon may provide a method to monitor Pem activity in vivo. To test this idea, we 
measured 3H-FLT uptake in NSCLC cells following 4 h Pem (5 µM) treatment (Figure 
2.7). 3H-FLT accumulation significantly increased in all cell lines (P < 0.01). However, 
24 h pretreatment with Dex (100 nM) abrogated this effect in Dex-sensitive cell lines.  
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Figure 2.7: Effect of Dex and Pem on 3H-FLT retention in NSCLC cell lines. NSCLC 
cells were grown in glucocorticoid-depleted media, treated 5 µM Pem with or without 
pretreatment with 100 nM Dex for 24 h. Cells were then transferred to media containing 
3H-FLT and incubated for 1 h. After washing, cells were lysed by KOH and the activity of 
samples was measured via liquid scintillation. All cell lines produced a significant flare 
after 4 h Pem treatment. When cells were pretreated with 24 h Dex, the flare was 
abolished in cells with high GRα expression (A549, H292, H226, recombinant cell line 
H1299-GRα). * P < 0.01   
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18F-FLT visualizes Dex interference with Pem activity   
To evaluate the flare effect in vivo¸ we utilized the same xenograft models as 
earlier experiments. Animals were imaged at baseline and again 4 h after receiving Pem 
(10 mg/kg) with or without pretreatment with Dex for 24 h. Mice were placed on a folate-
deficient diet to decrease serum folates to levels closer to humans simulate Pem 
efficacy observed in humans (253). As was observed in cell culture, 3H-FLT uptake 
increased from baseline after 4 h Pem (mean change in SUVmax of 48.9%), but this 
effect was abolished if animals received Dex pretreatment (mean change in SUVmax of   
-44.5%) (Figure 2.8) P < 0.01.  
Following 4 h Pem, H1299 tumors exhibited a greater flare from baseline than 
A549 xenografts: SUVmax in H1299 and H1299-GRα tumors increased by 107.3% and 
68.7%, respectively. If animals were pretreated with Dex, the flare response was 
completely eradicated H1299-GRα, and the change from baseline resembled that of 
animals treated with Dex alone. H1299 tumors still exhibited a significant flare from 
baseline (% change in SUVmax: 32.9%), but it was smaller than that produced by Pem 
alone, likely due to GR up-regulation, as seen before P < 0.01.   
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Figure 2.8A: Effect of Pem on 18F-FLT uptake in A549 xenografts. Mice were 
implanted with high-GRα A549 tumors and imaged at baseline and 4 h after injection 
with Pem (10 mg/kg, iv), with or without Dex pretreatment (15 mg/kg bid, ip) for 24 h. 
Representative images of a mouse bearing A549 tumors. In the top panel, tumor 
SUVmax increased by 52.9% after 4 h Pem. In the bottom panel, the flare response was 
completely abrogated, with tumor SUVmax decreasing by an average of 52.9%.  
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Figure 2.8B: Summary of the effect of Dex and Pem treatments on 18F-FLT 
retention in A549 tumors. SUVmax in control animals (n = 11 tumors) decreases by an 
average of 6.0% after 24 h. Following 24 h Dex (15 mg/kg bid, ip) (n = 9 tumors), tumor 
SUV decreases by 63.1%. 4 h Pem (10 mg/kg, iv) (n = 8 tumors) produces a mean 
increase of 48.9% in tumor 18F-FLT uptake, but this effect is abolished when animals 
are pretreated with Dex for 24 h (average change: -44.5%, n = 8 tumors). *P < 0.01.  
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Figure 2.9A: Effect of Pem on 18F-FLT uptake in H1299 xenografts. Mice were 
implanted with H1299 (top) or H1299-GRα (bottom) tumors and imaged at baseline and 
4 h after injection with Pem (10 mg/kg, iv), with or without Dex pretreatment (15 mg/kg 
bid, ip) for 24 h. Representative images from one animal with each condition are 
displayed. In mice bearing H1299 xenografts, there was a marked increase in 18F-FLT 
uptake after Pem with or without Dex pretreatment. Mice with H1299-GRα also 
demonstrated a sharp increase in tumor 18F-FLT uptake after Pem, but this effect was 
abolished if animals were pretreated with Dex for 24 h.  
  
Baseline 4 h Pem 4 h Pem Baseline 
Control 24 h Dex 
H
1
2
9
9
 
Change 
from  
Baseline 
(SUVmax) 
63.0% 125.9% 61.4% 68.8% 
H
1
2
9
9
-G
R
α
 
Change 
from  
Baseline 
(SUVmax) 
86.0% 128.6% -67.4% -56.8% 
S
U
V
 
5
0
  
48 
 
Figure 2.9B: Summary of the effect of Dex and Pem treatments on 18F-FLT 
retention in H1299 tumors. SUVmax in control animals (n = 8 tumors) decreases by an 
average of 1.0% after 24 h. Following 24 h Dex (15 mg/kg bid, ip) (n = 15 tumors), 
tumor SUV decreases by 20.1%. 4 h Pem (10 mg/kg, iv) (n = 8 tumors) produces a 
mean increase of 107.3% in tumor 18F-FLT uptake. This flare is reduced in magnitude 
when animals are pretreated with Dex (average change: 32.9%, n = 7 tumors), but still 
present. *P < 0.01.  
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Figure 2.8C: Summary of the effect of Dex and Pem treatments on 18F-FLT 
retention in H1299-GRα tumors. SUVmax in control animals (n = 9 tumors) decreases 
by an average of 3.7% after 24 h. Following 24 h Dex (15 mg/kg bid, ip) (n = 9 tumors), 
tumor SUV decreases by 41.3%. 4 h Pem (10 mg/kg, iv) (n = 8 tumors) produces a 
mean increase of 68.7% in tumor 18F-FLT uptake, but this effect is abolished when 
animals are pretreated with Dex for 24 h (average change: -42.9%, n = 8 tumors). *P < 
0.01.  
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DISCUSSION  
 
 Although widely used, Pem has proved to have a modest and variable effect in 
patients, with a median increase in progression-free survival of 5.3 months in the front-
line setting when combined with cisplatin, and only 3.3 months when used as a 
monotherapy in patients unable to tolerate platinum-based chemotherapy (236, 259). 
Furthermore, the 5-year survival for metastatic NSCLC remains dismal, at less than 4% 
(260). Given this paradigm, it is critical to identify factors that can be used to predict and 
optimize the clinical benefit of Pem in order to maximize efficacy and spare non-
responders the toxicity of ineffective chemotherapy. To that end, several studies have 
observed an association between low tumor expression of TS and better outcomes in 
patients treated with Pem (261). However, this has not been shown to be a powerful 
independent predictor of patient response to Pem, and is not used clinically (262).   
 A recent study by Patki et al. found that in a subset of NSCLC cell models, Dex 
reversibly inhibits entry of cells into the S-phase of the cell cycle resulting in the 
decreased expression of Pem targets TS and DHFR, as well as its membrane 
transporters: RFC and PCFT (224). Analysis of GRα in NSCLC biopsy specimens has 
indicated that there is an approximately equal distribution of tumors with high and low 
GRα expression (263). It possible that the protective effect of Dex, combined with 
differential tumor GRα expression may explain, in part, the variable efficacy of Pem in 
clinical practice.  
 Here, we explored the use of FLT retention as a direct functional probe to 
monitor Dex-mediated S-phase suppression in several models of NSCLC. Studies in 
NSCLC cell lines indicated that treatment with Dex for 24 h produced a significant 
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reduction in 3H-FLT uptake in cell lines with relatively high GRα expression. This result 
was translatable to animal studies, where implanted with high-GRα A549 tumors 
demonstrated an average change of -63.1% in SUVmax after 24 h Dex treatment. 
Furthermore, when imaging isogenic H1299 and H1299-GRα tumors, we found that the 
magnitude of change in 18F-FLT retention in response to Dex is correlated to the 
expression level of GRα. In patients with advanced NSCLC, the changes were much 
more variable, 2/4 patients showing some response to Dex. Furthermore, 18F-FLT PET 
was able to detect heterogeneity in Dex sensitivity between lesions within individual 
patients. The ability to simultaneously evaluate all tumor foci in patients is a major 
advantage of imaging compared to tissue analysis, given that NSCLC patients receiving 
chemotherapy have advanced disease.  
In addition, we sought to use FLT accumulation to monitor Pem activity through 
its inhibitory effect on TS, and subsequent increase in FLT accumulation. To that end, 
we found that 4 h Pem treatment produced a significant increase in 3H-FLT retention 
compared to control. This effect was found to be eradicated in high GRα-expressing 
cells if they were pretreated with Dex. This finding was corroborated with animal 
imaging. Mice bearing A549 and H1299-GRα tumors exhibited a significant flare from 
baseline after Pem treatment which was abolished if animals received Dex prior to 
chemotherapy. Conversely, low-GRα H1299 tumors produced a flare regardless of Dex 
treatment. Taken together, these data suggest that the presence of a flare in response 
to Pem may be indicative of the activity of the drug, and may be useful as an early 
marker for assessing response to therapy. A recent study in NSCLC patients treated 
with PEM attempted to correlate a flare in 18F-FLT uptake with drug efficacy. The 
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authors found that only 2/11 exhibited a flare, with the remaining individuals 
demonstrating either reduced or no change in tumor 18F-FLT uptake after Pem. 
Furthermore, the flare did not correlate with response to therapy (158). However, given 
that all patients on study received Dex prior to their treatment, this result is likely due to 
Dex-mediated suppression of TK1, which counteracts the compensatory rise in TdR 
salvage due to TS inhibition.  
Ultimately, the imaging approach used here could allow for the stratification of 
patient tumors by Dex sensitivity, and patients with sensitive cancers could be given a 
treatment regimen that does not require Dex prophylaxis. Alternatively, it may facilitate 
adjustment of the Dex treatment schedule so that the interference with therapy could be 
minimized while still preventing adverse events. In the bigger picture, numerous 
preclinical studies have found that GCs reduce the therapeutic effect of commonly used 
anti-neoplastic agents such as including cisplatin, doxorubicin, and gemcitabine, among 
others (219). 18F-FLT PET may facilitate examination of other chemotherapeutic agents, 
many of which are accompanied with GCs as part of supportive care.  
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CHAPTER 3 EFFECT OF CAPECITABINE TREATMENT ON THE UPTAKE OF 
THYMIDINE ANALOGS USING EXPLORATORY PET IMAGING AGENTS: FAU, 
FMAU, AND FLT 
 
BACKGROUND 
Capecitabine is a carbamate prodrug form of 5-FU, approved for the treatment of 
metastatic colorectal and breast cancers, and can be used as monotherapy or in 
combination with other cytotoxic and targeted agents (264, 265). Conversion to 5-FU is 
accomplished via the action of three enzymes: carboxylesterase, cytidine deaminase, 
and TP, the latter of which is found at higher concentrations in tumor cells than normal, 
healthy tissue (266, 267). Following conversion to 5-FU, anti-tumor activity is achieved 
via inhibition of TS and incorporation of 5-FU into RNA and DNA (267, 268). Despite its 
widespread use, additional research is needed to explore its mechanisms of 
cytotoxicity, activation, metabolism, and to develop methods to monitor efficacy.  
Due to its effects on TdR synthesis and incorporation pathways, capecitabine 
may alter the uptake and retention of TdR analogs used with PET imaging and this 
could provide a method for assessing response and understanding drug 
pharmacodynamics. In part, this is due to increased expression of TK1 in the pyrimidine 
salvage pathway, which is involved in the uptake and utilization of TdR from the plasma 
through phosphorylation.  Increased TK1 expression in tumors has been imaged with 
11C-TdR and TdR analogs such as FLT (137, 160, 269). FLT has been used to monitor 
cell proliferation (119, 270), since after uptake by tumor nucleoside transporters, FLT is 
phosphorylated by TK1, causing it to be trapped intracellularly (108, 118). Because FLT 
is minimally incorporated into DNA structure due to the lack of a 3’ hydroxyl, its retention 
principally reflects intracellular TK1 activity (115, 132, 271). Uptake of FLT is 
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reproducible and has been shown to be correlated with the proliferative marker Ki-67 in 
several neoplasms (119, 160, 246). 
FMAU is another analog of TdR that was originally introduced as an anti-viral and 
anti-neoplastic compound due to cytotoxicity following its incorporation into DNA (166, 
167). More recently, FMAU has been adapted to molecular imaging (160, 168). After 
entering the cell, FMAU is phosphorylated by mitochondrial TK2, and its uptake has 
found to be increased in response to conditions that cause an increase in mitochondrial 
mass, such as oxidative, reductive, and energy stress (167, 172, 173). Unlike FLT, 
which accumulates in highly proliferative tissues, FMAU is not retained in normal bone 
marrow, which may allow it to be useful in the detection and monitoring of bone marrow 
metastases.  Additionally, FMAU is cleared rapidly from the blood, allowing for a short 
imaging time and simplified kinetic analysis. 
FAU is a uracil analog that has been considered for cancer treatment due to its 
inhibitory effect on cell proliferation (169, 175, 176). After cells take up FAU, it is 
converted to FAU-MP and then to FMAU-MP via the action of TK1 and TS, respectively. 
Dependence on TS for activation may increase the specificity of FAU towards tumors 
with high expression of this enzyme, such as breast and colorectal cancers (177-179). 
Indeed, a recent pharmacokinetic modeling study found that conversion of FAU to 
FMAU is greatly increased in tumors compared to normal tissues (186). Moreover, 
increased TS expression has been found to be associated with poor therapeutic 
response in colorectal cancer, and therefore, high uptake of FAU may be a negative 
prognostic indicator in a subset of patients. Given the differences in metabolism for 
each of the tracers, the effects of capecitabine were expected to vary.  
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 The purpose of this study was to gauge the retention and usefulness of 
radiolabeled fluoropyrimidines FLT, FAU, and FMAU in the evaluation of patients with 
breast and gastrointestinal cancers who received capecitabine. The primary objective 
was to monitor changes in tracer uptake as measured by mean standardized uptake 
value (SUVmean) along with kinetic parameters. These parameters may provide an 
approximation of the physiological effect of capecitabine on tumors.  
MATERIALS AND METHODS 
Radiochemistry and Patient Imaging 
 PET tracers were synthesized as previously published and patients were injected 
intravenously with FLT (range, 347-389 MBq; mean 372 MBq), FAU (range, 211-396 
MBq; mean 346 MBq), or FMAU (range, 191-388 MBq; mean 339 MBq) over 60s as 
described (174, 254, 272). All subjects underwent dynamic PET with a series of timed 
images (4x20s, 4x40s, 4x60s, and 4x180s). In patients injected with FLT and FAU, but 
not FMAU, an additional series of images was collected (8x300s). PET was conducted 
with a 15-cm field of view over the area of the tumors (neck, thorax, or abdomen) 
followed by a whole body image using an Exact/HR tomograph (Siemens Medical 
Solutions, Malvern, Pennsylvania, USA).  
  Fifteen patients with solid tumors were imaged, five with each of the 18F-labeled 
PET tracers. Patient accrual alternated between the three agents based primarily on 
tracer availability. Tumor types were breast, colorectal, gastric, and esophageal 
cancers. Patients had not received therapy for at least 4 weeks prior to the first PET 
scan, and had not been previously treated with 5-FU, capecitabine or other fluorop 
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 yrimidines. Six of the fifteen patients studied received capecitabine alone. Other 
patients were placed on standard regimens, which utilized radiotherapy and oxaliplatin 
as well as targeted agents such as lapatinib, bevacizumab, and trastuzumab (Table 
3.1).  When capecitabine was combined with other treatments they were started after 
the third dose of capecitabine and after completion of the final PET scan. Patients 
underwent imaging within one week before therapy, and again one day after the start of 
therapy, after receiving three doses of capecitabine.  
 Patient images were analyzed with PMOD (Zurich, Switzerland) software and 
regions of interest (ROIs) were defined in a semi-automated fashion as published (168). 
ROIs were chosen in the three adjacent planes with the highest activity, using 
isocontours halfway between the minimum and maximum thresholds of the tumor. 
Tracer uptake was measured by standardized uptake value (SUV). Mean SUVs 
(SUVmean) were calculated on whole ROIs, and maximum SUVs (SUVmax) were 
measured as the pixels with the most activity in the same ROIs.  
 Kinetic Analysis  
Kinetic modeling was conducted using PMOD (Zurich, Switzerland) software as 
has been published previously (117). In short, FLT and FAU time-activity curves were 
fitted using a 3-compartment model, which produced rate constants K1, k2, and k3. K1 
(mL/g/min) represents the unidirectional transport of tracer from blood into tissue, k2 
(min-1) represents the reverse transport, and k3 (min-1) characterizes phosphorylation 
and intracellular trapping via TK1 activity. The flux values for FLT and FAU were then 
calculated as K1 x k3/(k2+k3). Tumor uptake values and blood tissue kinetics were 
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interpreted with respect to the blood activity level, obtained from measurements of 
tracer activity within great vessels.  
For FMAU kinetic analysis, we utilized tumor retention ratio (TRR), which has 
been shown to correlate strongly with compartmental-K. TRR was obtained by dividing 
the tumor FMAU activity—obtained in an image from 5 to 11 min post-injection—area 
under the curve (AUC) by of FMAU blood activity AUC. AUC values were calculated 
using GraphPad Prism version 6 (GraphPad Software, La Jolla, California, USA), which 
measures AUC using the trapezoid method. To reduce image noise, the first 5 minutes 
were omitted. Furthermore, we have previously shown that in FMAU blood activity 
decreases sharply in the first 11 minutes after injection, and that images taken within 
the 5-11 window are comparable to images from 50-60 minutes (168).  
Statistical Considerations 
 The relationship of one PET parameter to another was measured using linear 
regression models, and the goodness of fit of these models was assessed using the r2 
value. Regression models were fit and assessed using GraphPad Prism version 6 
(GraphPad Software, La Jolla, California, USA). 
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Table 3.1: Patient Characteristics 
Patient 
No. 
Age Sex 
Tumor 
Type 
Other Therapy with 
Capecitabine 
Tracer 
1 47 F Breast Lapatinib 
FLT 
2 65 F Breast None 
3 62 F Esophageal  Radiation, Irinotecan 
4 62 F Colorectal 
Bevacizumab, Oxaliplatin, 
Radiation 
5 56 F Colorectal Oxaliplatin 
6 63 F Breast None 
FMAU 
7 52 F Breast Lapatinib 
8 46 F Breast Lapatinib 
9 73 F Breast None 
10 63 F Breast None 
11 64 F Breast None 
FAU 
12 62 F Colorectal Oxaliplatin, Bevacizumab  
13 53 F Gastric None 
14 49 M Colorectal  Oxaliplatin, Radiation 
15 37 M Esophageal  Oxaliplatin, Trastuzumab 
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RESULTS 
FLT-PET imaging  
Five patients (median age: 62) with breast, esophageal, and colorectal 
carcinomas were imaged with 18F-FLT-PET at baseline, and then following capecitabine 
therapy. In addition to capecitabine, 4/5 patients underwent other anti-neoplastic 
therapy including: oxaliplatin, irinotecan, bevacizumab, lapatinib, and radiation after the 
second scan (Table 3.1). Variable changes in tumor activity were observed post-
treatment (Table 3.2). Patient 3 exhibited the largest change in SUVmean, with an 
increase of 172.3% from baseline (Figure 3.1). Patient 4 also had a marked change in 
tracer retention, with a SUV increase of 89.9% after capecitabine. The other three 
patients imaged had more modest changes in tumor SUV, ranging from an increase of 
19.4% to a decline of 25.4%. Although the primary endpoint was tracer uptake as 
measured by SUVmean, the changes observed correlated with changes in SUVmax (r2 = 
0.98, P = 0.0014). Although differences in tracer flux, calculated from compartmental-K, 
trended with changes in tumor SUV (Table 2), flux and SUVmean were not correlated 
(r2 = 0.57, P = 0.1404). 
Table 3.2: Tumor Retention in Patients Imaged with FLT 
Patient 
No. 
Tumor SUVmean Tracer Flux into Tumor (cc/min) 
Baseline 
Post-
Treatment 
% 
Change 
Baseline 
Post-
Treatment 
% 
Change 
1 1.97 1.58 -19.8 0.0271 0.0211 -22.1 
2 1.96 2.34 19.4 0.0314 0.0526 67.5 
3 4.7 12.8 172.3 0.0217 0.0796 266.8 
4 2.27 4.31 89.9 0.0187 0.109 482.9 
5 1.34 1 -25.4 0.0267 0.0213 -20.2 
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Figure 3.1: Tumor FLT Uptake in Patient 3. Axial (top) and coronal (bottom) FLT 
Images of a mediastinal metastasis (arrow) in a patient with esophageal cancer at 
baseline (A) and after 1 day of capecitabine therapy (B). Tumor SUVmean increased from 
4.70 to 12.80. 
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FMAU-PET imaging  
Five patients with breast cancer (median age: 63) were imaged with FMAU-PET at 
baseline and following capecitabine treatment. Two patients received laptinib after the 
start of capecitabine (Table 3.1). Although tumor activity was consistently high in 
patients imaged with 18F-FMAU (median SUVmean at baseline: 2.58), there was non-
specific tracer uptake throughout the lungs, which gave images a ‘grainy’ appearance 
(Figure 3.2). SUVmean values ranged from an increase in 23.1% to a decline of 24.4% 
with an average change of 0.2% (Table 3.3). SUVmean correlated strongly with SUVmax 
measurements (r2 = 0.95, P = 0.005). As mentioned, TRR was used for kinetic analysis 
in lieu of compartmental-K in patients imaged with FMAU because the rapid clearance 
of FMAU prevents the establishment of equilibrium between tissue compartments (168). 
Similarly to what was observed in patients imaged with FLT, differences in SUVmean and 
TRR after treatment trended in the same direction, but were not well correlated (r2 = 
0.65, P = 0.098). 
 
Table 3.3: Tumor Uptake in Patients Imaged with FMAU 
Patient 
No. 
Tumor SUVmean Tumor Retention Ratio 
Baseline 
Post-
Treatment 
% 
Change 
Baseline 
Post-
Treatment 
% 
Change 
6 4.64 5.06 9.1 3.01 3.47 15.3 
7 3.76 4.63 23.1 3.56 3.9 9.6 
8 1.97 2.11 7.1 2.18 2.74 25.7 
9 2.58 1.95 -24.4 2.03 1.65 -18.9 
10 2.14 1.84 -14 1.22 0.96 -21.3 
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Figure 3.2: Tumor FMAU Uptake in Patient 7. Axial (top) and coronal (bottom) FMAU 
Images of a lung metastasis (arrow) in a patient with breast cancer at baseline (A) and 
after 1 day of capecitabine therapy (B). Tumor SUVmean increased from 3.76 to 4.63. 
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FAU-PET Imaging  
Five patients (median age: 53) with breast, gastric, colorectal, and esophageal 
junction tumors underwent 18F-FAU-PET scans before and after capecitabine treatment. 
Two patients were on no other therapies, and the remaining three also received 
chemotherapy with either an antibody or radiation (Table 3.1). The majority of the 
patients showed little change in tracer uptake post-treatment (average change -10.2%) 
(Table 3.4). Only patient 15 displayed a notable change in FAU retention, with a decline 
of 40.3% after capecitabine (Figure 3.3). Like the previous tracers, FAU retention was 
high in the kidneys and liver, but greater non-specific tissue uptake was observed 
compared to patients imaged with FLT and FMAU. In addition, of the tracers studied, 
FAU had the lowest tumor activity. As with FLT, changes in SUVmean measurements 
correlated strongly with changes in SUVmax (r2 = 0.98, P = 0.001). Tracer flux was 
calculated for 4/5 patients, with patient 11 being not evaluable due to lack of dynamic 
imaging. As with the previous two tracers studied herein, in patients imaged with FAU, 
tracer flux and SUVmean were not significantly correlated (r2 = 0.72, P = 0.1534). 
Furthermore, mean pretreatment FAU flux values were far lower than what was 
observed with FLT (0.0.0059 cc/min versus 0.0251 cc/min), further underscoring the low 
tumor retention of FAU in this patient cohort.  
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Table 3.4: Tumor Retention in Patients Imaged with FAU 
Patient 
No. 
Tumor SUVmean Tracer Flux into Tumor (cc/min) 
Baseline 
Post-
Treatment 
% 
Change 
Baseline 
Post-
Treatment 
% 
Change 
11 1.03 1.06 2.9 No Dynamic Images 
12 1.05 0.87 -17.1 0.0032 0.0019 -40.6 
13 2.57 2.15 -16.3 0.0058 0.0055 -5.2 
14 1.82 2.17 19.2 0.0108 0.0158 46.3 
15 3.47 2.07 -40.3 0.0039 0.0029 -25.6 
 
  
  
65 
 
Figure 3.3: Tumor FAU Uptake in Patient 15. Axial (top) and coronal (bottom) FAU 
Images of an esophageal tumor (arrow) at baseline (A) and after 1 day of capecitabine 
therapy (B). Tumor SUVmean decreased from 3.47 to 2.12. 
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DISCUSSION 
Although several radiolabeled molecules have been developed for use with PET, 
FDG remains the principal approved compound for the detection and staging of cancer. 
Although FDG uptake correlates with general tumor metabolism, this may not accurately 
describe the proliferative capacity of cancers, which is a major consideration for 
treatment and prognosis. Further, because many chemotherapeutics used today 
function by impairing cellular proliferation, it is desirable to develop imaging modalities 
to monitor these pathways. Accordingly, we sought to examine the effect of 
capecitabine, a frequently used anti-neoplastic compound, on the uptake and retention 
of three nucleoside analogs. The goal of this study was to gain an increased 
understanding of the effect of capecitabine on tumor TdR metabolism, and to assess 
the usefulness of these tracers in the setting of cancer treatment.  
 A previous study in 9 non-small cell lung cancer patients found the error of FLT-
PET to approximately 20% (246). More recently, a multi-center trial examining the 
repeatability of FDG-PET in untreated patients found tumor SUV to vary between a 
decrease of 30% to an increase of 40% (273). Although, there have been no studies 
examining the repeatability of FMAU and FAU imaging, tumor uptake of these tracers is 
lower than FDG, and thus, one would not expect improved reproducibility.  
Patients imaged with FLT had a variable change in uptake after treatment, with 
two patients displaying a substantial increase in tumor retention (89.9 and 172.3%). 
Since FLT uptake reflects cellular TK1, the large increase in SUVmean indicates an 
upregulation of TK1 activity following capecitabine. This may be caused by the inhibitory 
effect of 5-FU on TS (152). As TdR levels drop due to TS inhibition, there is an increase 
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in TK1 activity as cells attempt to replenish TdR exogenously. This increase leads to a 
window of 1-24 hours in which FLT uptake is significantly increased, and has been 
termed the ‘flare’ phenomenon (154, 157). Conversely, the absence of change in FLT 
retention in the remaining three patients may suggest that capecitabine was unable to 
effectively block TS. This could be due to upregulation of intracellular TS levels leading 
to drug resistance, or inefficient conversion of capecitabine to 5-FU (274).  
 Subjects imaged with FMAU demonstrated little change in tracer retention after 
treatment. The average change in tumor SUVmean was 0.18% (range -24.4 to 23.1) 
(Table 3.3). Previous studies have shown increases in FMAU retention in response to 
oxidative, reductive, and energy stresses due to upregulation of mitochondrial TK2 
levels (245). Furthermore, it has been shown that anti-cancer agents can lead to an 
increase in in mitochondrial mass during apoptosis (275, 276).  Interestingly, patients 
imaged with FMAU had the highest baseline tumor uptake: 2.58 versus 2.45 in patients 
scanned with FLT and 1.99 patients scanned with FAU. These findings suggest that 
while tumor cells are under a high basal level of cellular stress, this is not increased 
significantly by short-term capecitabine treatment.  
Similar to patients imaged with FMAU, patients scanned with FAU demonstrated 
little change in tracer retention after capecitabine (Table 3.4), with an average change in 
SUVmean of -10.2%. No difference in measurement may be due to several factors, 
including elevated tumor TS. As discussed, high tumor TS is a common mechanism of 
treatment resistance in breast and colorectal cancers (182). In this case TS will continue 
to convert FAU-P to FMAU-P, with treatment having a negligible effect on this process. 
One patient demonstrated a decrease of 40.3% in tumor SUVmean from baseline in 
  
68 
response to capecitabine. This may be evidence of inhibition of TS by capecitabine, 
given that TS required for retention of FAU (175). This may signal some prognostic 
value to FAU-PET. It is worth noting, however, that FAU produced the lowest SUVs 
among the three tracers studied, suggesting a low level of tumor specificity.  
Despite small cohorts, differences in the imaging properties for these probes 
were found in response to capecitabine, a commonly used chemotherapeutic. These 
findings may have great implications regarding the cellular pathways within various 
tumors, and may prove useful in the generation of treatment biomarkers in the future. 
Unfortunately, the majority of the patients enrolled in this study were administered other 
treatments in addition to capecitabine, and therefore we are unable to make any 
determinations regarding patient response to therapy. Further studies are warranted to 
determine if the effects observed herein have prognostic significance.  
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CHAPTER 4 SUMMARY 
Imaging is an essential element in modern oncologic practice. It provides 
invaluable information needed for the diagnosis and staging of cancer, as well as for the 
optimization of treatment. Although anatomic imaging is the most prevalent form used in 
oncology and is the basis for RECIST, its limitations have led to the development of 
specialized probes and an expanded role for PET. PET allows for the in vivo 
assessment of the molecular pathways in cancer and therefore, a greater understanding 
of tumor physiology. While PET is still typically used with FDG to assess tumor 
metabolism, newer tracers can be used to visualize a variety of cellular processes.  
Aberrant cellular proliferation is a defining characteristic of cancer. Initial methods 
for assessing proliferation in patient cancers involved measurements conducted on 
patient biopsy samples. However, logistical issues associated with biopsy collection and 
the complex, heterogeneous nature of human malignancies have led to the 
development of imaging agents to monitor tumor proliferation. The most successful 
proliferation tracer to date has been FLT, which tracks proliferation through monitoring 
of the TdR salvage pathway. Cellular retention of FLT is mediated by the action of the 
highly S-phase-specific enzyme TK1, and FLT has been used to image the response of 
numerous anti-neoplastic treatments. Here, we sought to use FLT-PET to image the 
potential anti-proliferative effect of GCs.  
GCs are frequently used in the management of cancer, either as direct anti-
neoplastic therapy or for supportive care. However, a number of studies have shown 
that GCs such as Dex, through the action GRα, can produce cell cycle arrest in solid 
tumors, leading to chemotherapy resistance. This has prompted many to ask whether 
the use of GCs should be scaled back, despite their obvious value for the palliative care 
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of cancer patients. This question is especially pertinent in the setting of Pem treatment, 
in which all patients are administered Dex alongside their chemotherapy.  
To address this issue, we utilized FLT for the detection of Dex-mediated S-phase 
suppression using different models of NSCLC. In cell lines and human xenografts with 
high relative expression of GRα, a reversible decrease in FLT retention was observed 
following 24 h of Dex treatment, indicating that FLT accumulation can be used as a 
method for detecting Dex sensitivity. In NSCLC patients imaged with FLT, tracer 
retention was variable after 24 h Dex, with differences from patient-to-patient and 
between lesions within an individual. Taken together, these data suggest that the 
susceptibility to Dex-mediated cell cycle arrest is heterogeneous in patient disease, but 
that it can be detected using FLT-PET.  
In addition, we examined the FLT flare phenomenon, whereby TdR salvage is 
upregulated in response to inhibition of de novo TdR biosynthesis, in the context of Pem 
treatment. We found that while all cells produced a significant flare following Pem, this 
was abolished in high-GRα cells and human xenografts when chemotherapy was 
accompanied by Dex treatment. This adds support to the data indicating that Dex 
interferes with the activity of Pem, and demonstrates that this phenomenon can be 
monitored using FLT-PET. The flare effect is variable, however, as was shown in our 
studies conducted in patients with gastrointestinal and breast cancers treated with 
capecitabine. The flare was present in only 2/5 patients after chemotherapy.  
In addition, we explored the use of other fluoropyrimidine PET tracers: FMAU 
and FAU, which unlike FLT, can incorporate into DNA. FMAU is a TdR analog that is a 
substrate for TK2 and its uptake is reflective of cellular mitochondrial mass, which is 
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increased by cellular stress. FAU is a suicide prodrug of FMAU that requires TS, which 
is upregulated in many cancers, for activation. Although we observed a change from 
baseline in some patients imaged with FLT, tracer accumulation was largely unaffected 
in patients imaged with FMAU and FAU after capecitabine treatment, highlighting the 
differences in imaging properties between the agents.  
In conclusion, FLT continues to be a promising agent for imaging cellular 
proliferation, and this work presents a new potential application for the use of FLT-PET: 
the prediction of GC sensitivity in solid tumors. Further studies are likely needed to 
determine if the presence of a flare has value in assessing response to chemotherapy. 
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Imaging is critical in the detection and management of malignancies, and 
positron emission tomography (PET) is an imaging approach that provides information 
regarding cancer physiology through the tracking of molecular pathways and receptors.  
3’-fluoro-3’-deoxythymidine (FLT) is a PET tracer designed to image cellular 
proliferation, which is a hallmark of cancer. FLT has been used to study the response of 
cancer to a variety of treatments such as chemotherapy, targeted agents, and radiation.   
Here we explored FLT retention as a biomarker to monitor the anti-proliferative 
effect of the synthetic glucocorticoid (GC) dexamethasone (Dex) on non-small cell lung 
cancer (NSCLC). The basis for this work was the recent finding that Dex can cause 
reversible cell cycle arrest in a subset of NSCLC cells leading to chemotherapy 
resistance. A similar phenomenon has been shown in several other solid tumor models 
treated with GCs. Through studies of cell line models, human xenografts, and NSCLC 
patients, we observed that although the susceptibility to Dex-mediated cell cycle arrest 
is variable between cancers, it could be detected using FLT-PET. We also examined 
the FLT ‘flare’ phenomenon, in which FLT uptake is transiently increased following 
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treatment with drugs that reduce cellular thymidine synthesis. Two routinely used 
chemotherapeutic agents, pemetrexed and capecitabine, were found to produce 
marked increases in FLT accumulation, though the effect was variable in patients 
treated with capecitabine.   
The success of FLT led to the introduction of other thymidine analog PET tracers 
including 1-(2’-deoxy-2’-fluoro-β-D-arabinofuranosyl) thymidine (FMAU) and 1-(2’-
deoxy-2’-fluoro-β-D-arabinofuranosyl) uracil (FAU). Uptake of FMAU has been shown to 
be related to mitochondrial mass and cellular stress, while FAU is a prodrug that 
requires activation by thymidylate synthase. Although capecitabine treatment produced 
a change from baseline in patients imaged with FLT, tracer retention was unchanged in 
patients imaged with FMAU and FAU, highlighting the differences in imaging properties 
between the tracers.   
 In summary, FLT continues to show promise as a tool for the non-invasive 
monitoring of cellular proliferation, and may be a useful biomarker for the prediction of 
GC sensitivity in solid tumors. 
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AUTOBIOGRAPHICAL STATEMENT 
CHRISTOPHER I. MCHUGH 
 I enrolled in the MD/PhD program at the Wayne State University School of 
Medicine in the summer of 2011. After two years of medical school and a couple of 
graduate rotations I joined the research group of Dr. Anthony Shields. Although I didn’t 
know much about imaging at the time, I was interested in Dr. Shields’ work with positron 
emission tomography (PET) as a way to assess cancer therapy, an approach with 
which I was completely unfamiliar. In addition, I felt that Dr. Shields’ would be an 
especially good mentor for me since he is a practicing physician-scientist.  
 My work in the Shields laboratory has been the study of thymidine analog PET 
tracers, with a focus on 3’-fluoro-3’-deoxythymidine (FLT). Specifically, the goal of my 
studies was to use PET to monitor the response of cancer to chemotherapy. With Dr. 
Shields’ guidance, I gained an understanding of the field of nuclear imaging and 
developed my technical laboratory skills. I also learned to analyze patient and animal 
PET and computed tomography (CT) images. Throughout my training I collaborated 
with several clinical and scientific faculty at the Karmanos Cancer Institute, which 
helped to broaden my knowledge of chemotherapy and cancer as a whole.  
I was able to present my work twice at international imaging conferences, as well 
as internal meetings at Wayne State. In the coming years I will conclude my medical 
training and seek a research-focused residency position. Ultimately, I would like to be a 
faculty member at a major research hospital.  
 
